Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 12 mechanisms across 118 industry trials with a known mechanism of action.

See full pipeline →

Kinase Inhibitor

46 trials 20 active 12 sponsors

PIK3CA

9 trials 4 active 2 sponsors

Topoisomerase I/Trop-2

5 trials 4 active 1 sponsor

Estrogen Receptor Antagonist

11 trials 2 active 5 sponsors

Poly(ADP-Ribose) Polymerase Inhibitor

6 trials 2 active 1 sponsor

AKT1/AKT2/AKT3

3 trials 2 active 1 sponsor

Programmed Death Receptor-1 Blocking Antibody

13 trials 1 active 5 sponsors

Microtubule Inhibitor

9 trials 1 active 8 sponsors

Aromatase Inhibitor

7 trials 1 active 5 sponsors

Nucleoside Metabolic Inhibitor

7 trials 1 active 4 sponsors

Endoglycosidase

1 trials 1 active 1 sponsor

Hypoxia-inducible Factor Inhibitor

1 trials 1 active 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

1296 industry-sponsored trials across 475 sponsors

View full landscape →

Showing 30 of 30 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Roche	—	—	RECRUITING	2026-09-30	NCT06274515
AstraZeneca	Trastuzumab deruxtecan	—	RECRUITING	2026-10-31	NCT06429761
Novartis	Ribociclib	—	ACTIVE NOT RECRUITING	2030-06-28	NCT05161195
GE Healthcare	18F Fluoroestradiol Radiopharmaceutical with PET/CT	—	ACTIVE NOT RECRUITING	2025-04-18	NCT05486182
Jiangsu Famous Medical Technology Co., Ltd.	Dalpiciclib	—	NOT YET RECRUITING	2025-10-30	NCT06613373
Novartis	Alpelisib	PIK3CA	COMPLETED	2025-06-12	NCT05631795
AstraZeneca	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	COMPLETED	2022-09-30	NCT04330040
Roche	Carboplatin	Platinum-based Drug [EPC]	COMPLETED	2021-06-24	NCT02419742
Roche	Trastuzumab emtansine	—	COMPLETED	2019-12-14	NCT02658734
Pfizer	Palbociclib	Kinase Inhibitor [EPC]	COMPLETED	2019-07-25	NCT02679755
Lupin Ltd.	Lupin's Pegfilgrastim	—	COMPLETED	2019-01-09	NCT03511378
Roche	Docetaxel	Microtubules/Tubulin	COMPLETED	2018-09-26	NCT02445586
iOMEDICO AG	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2017-08-31	NCT02248571
Novartis	RAD001	—	COMPLETED	2016-08-15	NCT01743560
AstraZeneca	Fulvestrant	Estrogen Receptor Antagonist [EPC]	COMPLETED	2016-05-06	NCT02447328
Agendia	TAC chemotherapy	—	COMPLETED	2016-02	NCT01501487
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	PEG-rhG-CSF	—	COMPLETED	2016-02	NCT02805205
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	PEG-rhG-CSF	—	COMPLETED	2016-02	NCT02805153
Roche	Bevacizumab	Vascular Endothelial Growth Factor Inhibitor [EPC]	COMPLETED	2015-12	NCT01094184
Eisai Korea Inc.	Eribulin mesylate	Tubulin	COMPLETED	2015-07	NCT01961544
Xoft, Inc.	—	—	COMPLETED	2015-01	NCT00742222
Roche	Docetaxel	Microtubules/Tubulin	COMPLETED	2014-07	NCT01301729
Novartis	Zoledronic acid	Farnesyl pyrophosphate synthase	COMPLETED	2012-08	NCT01129336
Novartis	letrozole	Aromatase Inhibitor [EPC]	COMPLETED	2009-06	NCT00688909
Ethicon, Inc.	—	—	COMPLETED	2009-03	NCT00768222
Eli Lilly	Abemaciclib	Kinase Inhibitor [EPC]	TERMINATED	2020-08-11	NCT04031885
SenoRx, Inc.	—	—	TERMINATED	2011-03	NCT00699101
Eli Lilly	Abemaciclib	Kinase Inhibitor [EPC]	WITHDRAWN	2022-03-23	NCT03988114
Roche	bevacizumab [Avastin]	—	WITHDRAWN	2013-11	NCT00774241
Roche	bevacizumab [Avastin]	—	WITHDRAWN	2012-12	NCT01156961

Showing 100 of 287 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shanghai Pharmaceuticals Holding Co., Ltd	SPH4336 Tablets 400mg	—	RECRUITING	2026-05-31	NCT05744687
Olema Pharmaceuticals, Inc.	Palazestrant	—	RECRUITING	2026-06-30	NCT06016738
Shanghai JMT-Bio Inc.	JSKN003	—	RECRUITING	2026-10-13	NCT06846437
InventisBio Co., Ltd	D-0502	—	RECRUITING	2026-11-30	NCT06954961
Greenwich LifeSciences, Inc.	GLSI-100	—	RECRUITING	2026-12	NCT05232916
Akeso	AK112	—	RECRUITING	2026-12	NCT06767527
Shandong Suncadia Medicine Co., Ltd.	HRS-8080 Tablet	—	RECRUITING	2026-12	NCT07024173
Shanghai Pharmaceuticals Holding Co., Ltd	SPH4336 Tablets	—	RECRUITING	2026-12-01	NCT05860465
Shanghai JMT-Bio Inc.	KN026	—	RECRUITING	2026-12-16	NCT06747338
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	RECRUITING	2026-12-31	NCT06081959
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2026-12-31	NCT05894239
Roche	Giredestrant	—	RECRUITING	2027-02-19	NCT06065748
LeonaBio	Lasofoxifene in combination with abemaciclib	—	RECRUITING	2027-04	NCT05696626
AstraZeneca	Camizestrant	—	RECRUITING	2027-04-20	NCT05774951
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M07D1	—	RECRUITING	2027-05	NCT06957886
Qilu Pharmaceutical Co., Ltd.	ESG401	—	RECRUITING	2027-06	NCT06732323
Qilu Pharmaceutical Co., Ltd.	ESG401	—	RECRUITING	2027-06-30	NCT06383767
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	SKB264	—	RECRUITING	2027-07	NCT07071337
Biotheus Inc.	PM8002	—	RECRUITING	2027-07	NCT06419621
Pfizer	PF-07248144	—	RECRUITING	2027-07-22	NCT07062965
AstraZeneca	Dato-DXd	—	RECRUITING	2027-07-28	NCT06103864
Daiichi Sankyo	Trastuzumab Deruxtecan	—	RECRUITING	2027-10-01	NCT05950945
AstraZeneca	Capivasertib	AKT1/AKT2/AKT3	RECRUITING	2027-11-01	NCT04862663
BriaCell Therapeutics Corporation	SV-BR-1-GM	—	RECRUITING	2027-12	NCT06072612
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811 for Injection	—	RECRUITING	2027-12	NCT07196774
Shanghai Henlius Biotech	HLX87 + HLX22	—	RECRUITING	2028-01-15	NCT07294508
AstraZeneca	Dato-DXd	—	RECRUITING	2028-02-02	NCT07205822
Suzhou Suncadia Biopharmaceuticals Co., Ltd.	SHR-A1811 for Injection	—	RECRUITING	2028-03	NCT07111832
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 Injection	—	RECRUITING	2028-03	NCT07008976
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2028-04-28	NCT06435429
Relay Therapeutics, Inc.	RLY-2608	—	RECRUITING	2028-04-30	NCT06982521
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2930+ chemotherapy	—	RECRUITING	2028-06	NCT07047365
Jiangsu Simcere Pharmaceutical Co., Ltd.	SIM0270	—	RECRUITING	2028-08-31	NCT06680921
Olema Pharmaceuticals, Inc.	Palazestrant	—	RECRUITING	2028-12	NCT07085767
Shandong Suncadia Medicine Co., Ltd.	HRS-8080 Tablet ; Dalpiciclib Isethionate	—	RECRUITING	2028-12	NCT07354022
AstraZeneca	Saruparib (AZD5305)	—	RECRUITING	2029-03-30	NCT06380751
Celcuity Inc	Arm A: Gedatolisib + Palbociclib + Fulvestrant	—	RECRUITING	2029-03-31	NCT06757634
Risen (Suzhou) Pharma Tech Co., Ltd.	JS105	—	RECRUITING	2029-05-31	NCT07207070
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 for Injection	—	RECRUITING	2029-07	NCT07003074
Stemline Therapeutics, Inc.	Elacestrant	—	RECRUITING	2029-08	NCT06492616
Novartis	Ribociclib	—	RECRUITING	2029-09-07	NCT05827081
AstraZeneca	Camizestrant	—	RECRUITING	2030-03-04	NCT05952557
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	RECRUITING	2030-04	NCT06126640
Shandong Suncadia Medicine Co., Ltd.	HRS-8080 Tablets	—	RECRUITING	2030-12	NCT07349069
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2032-05-30	NCT06790693
Shanghai JMT-Bio Inc.	KN026	—	RECRUITING	2034-08-07	NCT07441460
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	JSKN003	—	RECRUITING	2026-04-01	NCT06079983
Genor Biopharma Co., Ltd.	GB491 combined with Letrozole	—	RECRUITING	2026-01-30	NCT05851014
BeBetter Med Inc	BEBT-209 capsules	—	RECRUITING	2025-12-31	NCT06998108
Tianjin Hemay Pharmaceutical Co., Ltd	Hemay022+AI	—	RECRUITING	2025-12	NCT06313983
Shanghai Yizhong Pharmaceutical Co., Ltd.	Paclitaxel Polymeric Micelles for Injection	—	RECRUITING	2025-12	NCT06143553
Shanghai JMT-Bio Inc.	Recombinant Humanized Bispecific antibody against HER2，KN026	—	RECRUITING	2025-07-31	NCT05838066
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	RECRUITING	2025-01-30	NCT05814354
Celcuity Inc	Gedatolisib	—	ACTIVE NOT RECRUITING	2026-06-30	NCT05501886
AstraZeneca	Trastuzumab deruxtecan	—	ACTIVE NOT RECRUITING	2026-07-06	NCT04784715
AstraZeneca	AZD9833	—	ACTIVE NOT RECRUITING	2026-08-24	NCT04711252
Laekna Limited	Afuresertib	—	ACTIVE NOT RECRUITING	2026-10-30	NCT04851613
AstraZeneca	Capivasertib	AKT1/AKT2/AKT3	ACTIVE NOT RECRUITING	2026-10-31	NCT06635447
Immutep S.A.S.	eftilagimod alpha	—	ACTIVE NOT RECRUITING	2026-10-31	NCT05747794
Jiangsu HengRui Medicine Co., Ltd.	SHR6390	—	ACTIVE NOT RECRUITING	2026-10-31	NCT04842617
Roche	Inavolisib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-11-13	NCT05646862
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen	—	ACTIVE NOT RECRUITING	2026-12	NCT05780567
Gilead	Sacituzumab Govitecan-hziy	Topoisomerase I/Trop-2	ACTIVE NOT RECRUITING	2026-12	NCT04639986
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Raloxifene - Usual	—	ACTIVE NOT RECRUITING	2026-12-18	NCT06062810
Pfizer	Vepdegestrant (ARV-471/PF-07850327)	—	ACTIVE NOT RECRUITING	2026-12-30	NCT05909397
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05424835
Novartis	Alpelisib	PIK3CA	ACTIVE NOT RECRUITING	2027-01-28	NCT05038735
Novartis	Alpelisib	PIK3CA	ACTIVE NOT RECRUITING	2027-02-26	NCT04208178
AstraZeneca	Olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2027-04-06	NCT04421963
AstraZeneca	Dato-DXd	—	ACTIVE NOT RECRUITING	2027-09-20	NCT05629585
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811 Injection	—	ACTIVE NOT RECRUITING	2027-10	NCT06057610
Roche	Phesgo	Endoglycosidase [EPC]	ACTIVE NOT RECRUITING	2027-10-31	NCT05296798
AstraZeneca	Fulvestrant	Estrogen Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2027-12-31	NCT06764186
Gilead	Sacituzumab Govitecan-hziy	Topoisomerase I/Trop-2	ACTIVE NOT RECRUITING	2028-04	NCT05840211
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2028-08-31	NCT04873362
AstraZeneca	Dato-DXd	—	ACTIVE NOT RECRUITING	2028-11-20	NCT06112379
Pfizer	PF-07220060	—	ACTIVE NOT RECRUITING	2029-01-02	NCT06760637
Novartis	Ribociclib	—	ACTIVE NOT RECRUITING	2030-05-29	NCT03701334
Merck	Pembrolizumab (K)	—	ACTIVE NOT RECRUITING	2031-01-24	NCT03725059
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	ACTIVE NOT RECRUITING	2026-05	NCT06343948
DualityBio Inc.	DB-1303/BNT323	—	ACTIVE NOT RECRUITING	2026-05	NCT06018337
Tolmar Inc.	TOL2506	—	ACTIVE NOT RECRUITING	2026-04-30	NCT04906395
Roche	Giredestrant	—	ACTIVE NOT RECRUITING	2026-01-30	NCT04546009
Xuanzhu Biopharmaceutical Co., Ltd.	XZP-3287+ Letrozole/Anastrozole	—	ACTIVE NOT RECRUITING	2025-12-05	NCT05257395
Changchun GeneScience Pharmaceutical Co., Ltd.	T Leuprolide Injectable Emulsion	—	ACTIVE NOT RECRUITING	2025-11	NCT06449027
R-Pharm	RPH-051	—	ACTIVE NOT RECRUITING	2025-10-23	NCT07386938
Seagen, a wholly owned subsidiary of Pfizer	Tucatinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2025-09-05	NCT05132582
AstraZeneca	Dato-DXd	—	ACTIVE NOT RECRUITING	2025-08-25	NCT05374512
Roche	Giredestrant	—	ACTIVE NOT RECRUITING	2025-08-08	NCT04961996
Roche	Giredestrant	—	ACTIVE NOT RECRUITING	2025-07-16	NCT05306340
Daiichi Sankyo	DS-8201a	—	ACTIVE NOT RECRUITING	2025-07-02	NCT04622319
AstraZeneca	AZD9833	—	ACTIVE NOT RECRUITING	2025-06-30	NCT04964934
Biocad	BCD-178	—	ACTIVE NOT RECRUITING	2025-06-06	NCT05802225
AstraZeneca	Trastuzumab Deruxtecan	—	ACTIVE NOT RECRUITING	2025-03-12	NCT05113251
Pfizer	ARV-471	—	ACTIVE NOT RECRUITING	2025-01-31	NCT05654623
BioRay Pharmaceutical Co., Ltd.	HS627	—	ACTIVE NOT RECRUITING	2024-09-11	NCT04514419
AstraZeneca	Dato-DXd	—	ACTIVE NOT RECRUITING	2024-07-24	NCT05104866
Shanghai Henlius Biotech	HLX11	—	ACTIVE NOT RECRUITING	2024-05-15	NCT05346224
AstraZeneca	Trastuzumab deruxtecan	—	ACTIVE NOT RECRUITING	2024-03-18	NCT04494425
Xuanzhu Biopharmaceutical Co., Ltd.	XZP-3287+Fulvestrant	—	ACTIVE NOT RECRUITING	2024-02-22	NCT05077449

Showing 100 of 541 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Shandong Suncadia Medicine Co., Ltd.	HRS-8080; Dalpiciclib Isethionate Tablets	—	RECRUITING	2026-06	NCT06167694
RemeGen Co., Ltd.	Disitamab Vedotin Injection	—	RECRUITING	2026-06	NCT06178159
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 for injection	—	RECRUITING	2026-06	NCT06452706
BeBetter Med Inc	BEBT-209 capsules	—	RECRUITING	2026-06-30	NCT06685796
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202 should be intravenously infused	—	RECRUITING	2026-07-30	NCT06439771
Jacobio Pharmaceuticals Co., Ltd.	JAB-2485 (Aurora A inhibitor)	—	RECRUITING	2026-08	NCT05490472
AtlasMedx, Incorporated	AMXI-5001:Dose Escalation Phase I	—	RECRUITING	2026-08	NCT04503265
PMV Pharmaceuticals, Inc	rezatapopt	—	RECRUITING	2026-08-15	NCT04585750
Nantong Bencao Quadriga Medical Technology Co. Ltd.	NBQ72S	—	RECRUITING	2026-08-31	NCT06810804
Phoenix Molecular Designs	PMD-026	—	RECRUITING	2026-09	NCT04115306
Processa Pharmaceuticals	PCS6422 and capecitabine	—	RECRUITING	2026-09	NCT06568692
TYK Medicines, Inc	TYK-00540	—	RECRUITING	2026-09	NCT06950086
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202 for injection; Toripalimab injection	—	RECRUITING	2026-09-01	NCT07169994
RemeGen Co., Ltd.	Disitamab Vedotin	—	RECRUITING	2026-10-01	NCT06642545
Shandong Suncadia Medicine Co., Ltd.	HRS-2189	—	RECRUITING	2026-10-30	NCT06679036
Shandong Suncadia Medicine Co., Ltd.	HRS-8080; SHR-A1811	—	RECRUITING	2026-10-31	NCT06222879
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202 should be intravenously infused	—	RECRUITING	2026-11	NCT06107686
Atossa Therapeutics, Inc.	(Z)-endoxifen	—	RECRUITING	2026-11	NCT05607004
SynDevRx, Inc.	Evexomostat	—	RECRUITING	2026-12	NCT05455619
858 Therapeutics, Inc.	ETX-19477	—	RECRUITING	2026-12	NCT06395519
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2026-12	NCT06042894
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQB2930 for injection	—	RECRUITING	2026-12	NCT06202261
Stemline Therapeutics, Inc.	Elacestrant	—	RECRUITING	2026-12-27	NCT05563220
Shanghai Pharmaceuticals Holding Co., Ltd	SPH4336 Tablets	—	RECRUITING	2026-12-31	NCT05872347
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2026-12-31	NCT06695845
Rhizen Pharmaceuticals SA	Tenalisib	—	RECRUITING	2026-12-31	NCT06189209
Marengo Therapeutics, Inc.	STAR0602	—	RECRUITING	2027-01	NCT06827613
Biostar Pharma, Inc.	Utidelone	—	RECRUITING	2027-01-15	NCT06764940
Beijing Biotech	Dual-target CAR-NK cells (EB-DT-CAR-NK)	—	RECRUITING	2027-02-14	NCT07486089
Beijing Biotech	Dual-target CAR-NK cells	—	RECRUITING	2027-03-14	NCT07510802
Merck	Belzutifan	Hypoxia-inducible Factor Inhibitor [EPC]	RECRUITING	2027-05-05	NCT06428396
ITM Oncologics GmbH	[68Ga]Ga-DPI-4452	—	RECRUITING	2027-06	NCT05706129
Criterium, Inc.	Tucatinib	Kinase Inhibitor [EPC]	RECRUITING	2027-06-01	NCT05458674
Shanghai Henlius Biotech	HLX22	—	RECRUITING	2027-06-01	NCT06832202
Ensem Therapeutics	ETX-636 dose escalation	—	RECRUITING	2027-06-30	NCT06993844
TransThera Sciences (Nanjing), Inc.	Tinengotinib at the optimal dose combined with Fulvestrant	—	RECRUITING	2027-06-30	NCT07498478
Puma Biotechnology, Inc.	Alisertib	—	RECRUITING	2027-06-30	NCT06369285
Jiangsu Alphamab Biopharmaceuticals Co., Ltd	JSKN016	—	RECRUITING	2027-06-30	NCT06942234
Genmab	Rina-S	—	RECRUITING	2027-07	NCT05579366
Incyclix Bio	INX-315	—	RECRUITING	2027-07	NCT05735080
Hummingbird Bioscience	ENV-501	—	RECRUITING	2027-07	NCT06956690
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2027-07-31	NCT07054190
AstraZeneca	AZD8421	—	RECRUITING	2027-08-04	NCT06188520
Daiichi Sankyo	HER3-DXd	—	RECRUITING	2027-09-01	NCT06172478
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	A166	—	RECRUITING	2027-09-20	NCT07299825
AstraZeneca	AZD8205	—	RECRUITING	2027-09-29	NCT05123482
Pfizer	Disitamab vedotin	—	RECRUITING	2027-10-25	NCT06966453
Filamon LTD	A novel hGIIA-Vimentin Inhibitor	—	RECRUITING	2027-10-26	NCT06926075
ALX Oncology Inc.	Evorpacept (ALX148)	—	RECRUITING	2027-12	NCT07007559
Radiopharm Theranostics, Ltd	177Lu-BetaBart	—	RECRUITING	2027-12	NCT07189871
Criterium, Inc.	Palbociclib	Kinase Inhibitor [EPC]	RECRUITING	2027-12-31	NCT04567420
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	GTAEXS617	—	RECRUITING	2028-01	NCT05985655
Jazz Pharmaceuticals	Zanidatamab	—	RECRUITING	2028-01-01	NCT07102381
Blue Earth Diagnostics	[18F]FPyQCP	—	RECRUITING	2028-01-31	NCT07432633
Avenzo Therapeutics, Inc.	AVZO-021	—	RECRUITING	2028-01-31	NCT05867251
Ellipses Pharma	EP0062	—	RECRUITING	2028-02	NCT05573126
Aminex Therapeutics, Inc.	AMXT 1501 Dicaprate	—	RECRUITING	2028-02-28	NCT07287917
BioNTech SE	BNT323	—	RECRUITING	2028-05	NCT06827236
Forward Pharmaceuticals Co., Ltd.	FWD1802	—	RECRUITING	2028-05-01	NCT07002177
Jiangsu HengRui Medicine Co., Ltd.	Trastuzumab Rezetecan for Injection	—	RECRUITING	2028-06	NCT07497386
ModeX Therapeutics, An OPKO Health Company	MDX2001	—	RECRUITING	2028-08	NCT06239194
Avenzo Therapeutics, Inc.	AVZO-021	—	RECRUITING	2028-08	NCT06998407
Tanabe Pharma America, Inc.	MT-4561	—	RECRUITING	2028-08	NCT06943521
Roche	GDC-4198	—	RECRUITING	2028-08-31	NCT07100106
Shenzhen Majory Biotechnology Co., Ltd.	MR001 Bispecific Antibody for Injection	—	RECRUITING	2028-09-01	NCT07208149
Novartis	ECI830	—	RECRUITING	2028-09-25	NCT06726148
Qilu Pharmaceutical Co., Ltd.	QLS1304 tablet+Fulvestrant or QLC1401	—	RECRUITING	2028-11-02	NCT07235176
Shandong Suncadia Medicine Co., Ltd.	HRS-6208 Capsule	—	RECRUITING	2028-12	NCT07389733
Tubulis GmbH	TUB-030	—	RECRUITING	2028-12	NCT06657222
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2028-12-19	NCT07405801
Acerand Therapeutics (Shanghai) Limited	ACE-86225106 tablet	—	RECRUITING	2028-12-21	NCT06380660
Terremoto Biosciences Inc.	TER-2013	—	RECRUITING	2028-12-30	NCT07109726
Boehringer Ingelheim	Zongertinib	Kinase Inhibitor [EPC]	RECRUITING	2029-01-08	NCT06324357
Faeth Therapeutics	Serabelisib	—	RECRUITING	2029-05	NCT07558733
Delcath Systems Inc.	Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)	—	RECRUITING	2029-05	NCT06875128
Roche	Giredestrant	—	RECRUITING	2029-05-30	NCT04802759
Pfizer	PF-07248144	—	RECRUITING	2029-07-13	NCT04606446
Seagen, a wholly owned subsidiary of Pfizer	disitamab vedotin	—	RECRUITING	2029-07-28	NCT06157892
Minghui Pharmaceutical (Hangzhou) Ltd	MHB036C for Injection	—	RECRUITING	2029-08	NCT07130383
MBrace Therapeutics	ADC	—	RECRUITING	2029-09-30	NCT07145255
Merck	Patritumab deruxtecan	—	RECRUITING	2029-12-31	NCT06797635
IDEAYA Biosciences	IDE574	—	RECRUITING	2030-03-30	NCT07540572
Merck	Patritumab deruxtecan	—	RECRUITING	2030-04-18	NCT06686394
Eli Lilly	STX-478	—	RECRUITING	2030-07	NCT05768139
Roche	Capecitabine	Nucleoside Metabolic Inhibitor [EPC]	RECRUITING	2030-09-30	NCT03424005
Bristol-Myers Squibb	BMS-986507	—	RECRUITING	2031-02-26	NCT06618287
Novartis	GVV858	—	RECRUITING	2031-05-09	NCT07288359
Novartis	[68Ga]Ga-NeoB	—	RECRUITING	2031-09-09	NCT06247995
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2031-10-31	NCT07368998
Forward Pharmaceuticals Co., Ltd.	FWD1802	—	RECRUITING	2026-03	NCT06064812
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2025-12-31	NCT06006390
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	VB15010	—	RECRUITING	2025-12-30	NCT06819215
Jiangsu HengRui Medicine Co., Ltd.	HRS-6209 Capsules	—	RECRUITING	2025-12	NCT06974929
Jiangsu HengRui Medicine Co., Ltd.	HRS-6209 in Combination with Fulvestrant	—	RECRUITING	2025-12	NCT06555068
RemeGen Co., Ltd.	Disitamab Vedotin Injection （18 weeks）	—	RECRUITING	2025-12	NCT06227117
GI Innovation, Inc.	GI-102 subcutaneous (SC)	—	RECRUITING	2025-11-12	NCT05824975
Abscint NV/SA	—	—	RECRUITING	2025-09	NCT06369831
RemeGen Co., Ltd.	Disitamab Vedotin for Injection	—	RECRUITING	2025-06-01	NCT06389006
GeneMedicine Co., Ltd.	GM103 (Part A)	—	RECRUITING	2025-05-30	NCT06265025
BriaCell Therapeutics Corporation	BC1 cell line	—	RECRUITING	2025-04-30	NCT06471673

Showing 100 of 438 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Stemline Therapeutics, Inc.	MEN2312	—	RECRUITING	2026-06	NCT06638307
SAPU NANO (US) LLC	Sapu003	—	RECRUITING	2026-06	NCT07369505
A&G Pharmaceutical Inc.	AG-01 Compound	—	RECRUITING	2026-06	NCT05627960
OnKure, Inc.	OKI-219	—	RECRUITING	2026-06-01	NCT06239467
Avacta Life Sciences Ltd	AVA6000	—	RECRUITING	2026-06-15	NCT04969835
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	SYN818	—	RECRUITING	2026-06-30	NCT06666270
Epsilogen Ltd	MOv18 IgE	—	RECRUITING	2026-07	NCT06547840
Radionetics Oncology	68Ga-R10602 injection	—	RECRUITING	2026-07	NCT06745804
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B16D1	—	RECRUITING	2026-07	NCT06493864
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M17D1	—	RECRUITING	2026-08	NCT06503783
Nurix Therapeutics, Inc.	NX-1607	—	RECRUITING	2026-08-31	NCT05107674
Angiex, Inc.	AGX101	—	RECRUITING	2026-09-06	NCT06440005
Regor Pharmaceuticals Inc.	RGT-419B	—	RECRUITING	2026-09-30	NCT05304962
IDEAYA Biosciences	IDE-161	—	RECRUITING	2026-10	NCT05787587
Sichuan Baili Pharmaceutical Co., Ltd.	GNC-077	—	RECRUITING	2026-10	NCT06609187
DIGMBIO	DM5167	—	RECRUITING	2026-10-30	NCT07101601
Kind Pharmaceuticals LLC	AND019 PO QD	—	RECRUITING	2026-11	NCT05187832
Shanghai Juncell Therapeutics	Engineering Tumor Infiltrating Lymphocytes	—	RECRUITING	2026-11-01	NCT06375187
Exelixis	XB010	—	RECRUITING	2026-11-23	NCT06545331
TerSera Therapeutics LLC	ZOLADEX	GnRH	RECRUITING	2026-11-30	NCT07310420
Iksuda Therapeutics Ltd.	IKS014	—	RECRUITING	2026-12	NCT05872295
Mersana Therapeutics	XMT-1660	—	RECRUITING	2026-12	NCT05377996
ExpreS2ion Biotechnologies	ES2B-C001	—	RECRUITING	2026-12	NCT06746688
NextCure, Inc.	LNCB74	—	RECRUITING	2026-12	NCT06774963
Sichuan Baili Pharmaceutical Co., Ltd.	BL-B01D1	—	RECRUITING	2026-12	NCT05470348
Sichuan Baili Pharmaceutical Co., Ltd.	BL-M07D1	—	RECRUITING	2026-12	NCT05461768
SillaJen, Inc.	BAL0891	—	RECRUITING	2026-12-24	NCT05768932
Alterome Therapeutics, Inc.	ALTA2618	—	RECRUITING	2026-12-29	NCT06533059
Novartis	[68Ga]Ga-NeoB	—	RECRUITING	2026-12-30	NCT05870579
Nanjing Sanhome Pharmaceutical, Co., Ltd.	SH009	—	RECRUITING	2026-12-30	NCT07390838
SystImmune Inc.	BL-B01D1	—	RECRUITING	2026-12-31	NCT05983432
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2026-12-31	NCT06043466
Orano Med LLC	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Solve Therapeutics	SLV-154	—	RECRUITING	2027-01	NCT06771219
Affibody	[177Lu]Lu-ABY-271	—	RECRUITING	2027-01-01	NCT07081555
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Mersana Therapeutics	XMT-2056	—	RECRUITING	2027-04	NCT05514717
Accent Therapeutics	ATX-295	—	RECRUITING	2027-04-30	NCT06799065
Relay Therapeutics, Inc.	RLY-2608	—	RECRUITING	2027-04-30	NCT05216432
Normunity AccelCo, Inc.	NRM-823	—	RECRUITING	2027-05-30	NCT07182149
Olema Pharmaceuticals, Inc.	OP-3136	—	RECRUITING	2027-05-30	NCT06784193
BeOne Medicines	BGB-21447	—	RECRUITING	2027-07-30	NCT06756932
NiKang Therapeutics, Inc.	NKT5097 CDK2/CDK4 dual degrader	—	RECRUITING	2027-07-31	NCT07029399
OncoTherapy Science, Inc.	OTS167PO	—	RECRUITING	2027-09	NCT02926690
Biotheryx, Inc.	BTX-9341	—	RECRUITING	2027-09-30	NCT06515470
Totus Medicines	TOS-358	—	RECRUITING	2027-12	NCT05683418
Aktis Oncology, Inc.	[225Ac]Ac-AKY-1189 (therapeutic)	—	RECRUITING	2027-12	NCT07020117
Iambic Therapeutics, Inc	IAM1363	—	RECRUITING	2027-12	NCT06253871
Clasp Therapeutics, Inc.	CLSP-1025	—	RECRUITING	2027-12	NCT06778863
Oscotec Inc.	OCT-598	—	RECRUITING	2027-12	NCT07358806
Sichuan Baili Pharmaceutical Co., Ltd.	Lutetium [177Lu] BL-ARC001	—	RECRUITING	2027-12	NCT07274852
Nammi Therapeutics Inc	QXL138AM Injection every 2 weeks by IV Infusion	—	RECRUITING	2027-12-31	NCT06582017
Olema Pharmaceuticals, Inc.	Palazestrant	—	RECRUITING	2027-12-31	NCT05508906
Fate Therapeutics	FT836	—	RECRUITING	2028-01	NCT07216105
Cellectar Biosciences, Inc.	Iopofosine I 131	—	RECRUITING	2028-02	NCT07311993
BeiGene	BG-68501	—	RECRUITING	2028-04	NCT06257264
Regor Pharmaceuticals Inc.	RGT-490	—	RECRUITING	2028-04	NCT07524322
Halda Therapeutics OpCo, Inc.	HLD-0117	—	RECRUITING	2028-04-30	NCT07524855
Cogent Biosciences, Inc.	CGT4255	—	RECRUITING	2028-05	NCT07361562
MacroGenics	MGC026 Dose Escalation	—	RECRUITING	2028-05	NCT06242470
Radionetics Oncology	68Ga-R11228	—	RECRUITING	2028-06-01	NCT07121244
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	SYN818 and Olaparib will be administered	—	RECRUITING	2028-08-25	NCT07156253
BeOne Medicines	BGB-43395	—	RECRUITING	2028-11	NCT06120283
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	BBO-10203	—	RECRUITING	2028-11	NCT06625775
ProteinQure Inc.	PQ203	—	RECRUITING	2028-12	NCT07190469
General Oncology, Inc.	Melphalan	—	RECRUITING	2028-12	NCT04150042
Bristol-Myers Squibb	BMS-986500	—	RECRUITING	2028-12-14	NCT06997029
SystImmune Inc.	BL-M07D1	—	RECRUITING	2028-12-15	NCT06293898
NiKang Therapeutics, Inc.	NKT3964	—	RECRUITING	2029-01	NCT06586957
Boundless Bio, Inc.	BBI-940	—	RECRUITING	2029-02-28	NCT07408089
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS74539	—	RECRUITING	2029-03	NCT07517198
Pfizer	PF-08032562	—	RECRUITING	2029-04-14	NCT07318805
Novartis	68Ga-NNS309	—	RECRUITING	2029-05-09	NCT07261631
AstraZeneca	Autologous, engineered T Cells targeting TP53 R175H	—	RECRUITING	2029-07-31	NCT05877599
BeOne Medicines	BG-75202	—	RECRUITING	2029-09-30	NCT07222267
Conjupro Biotherapeutics, Inc.	SYS6043	—	RECRUITING	2029-12	NCT07424547
Roche	GDC-0587	—	RECRUITING	2030-06-01	NCT07214662
Novartis	[68Ga]Ga-NNS309	—	RECRUITING	2031-01-15	NCT06562192
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10502 + NHA	—	RECRUITING	2026-05-07	NCT06769425
Edgewood Oncology Inc.	BTX-A51	—	RECRUITING	2026-05	NCT04872166
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10502	—	RECRUITING	2026-04-01	NCT05740956
Shanghai Best-Link Bioscience, LLC	BL0175	—	RECRUITING	2026-02-20	NCT06738966
Shandong Boan Biotechnology Co., Ltd	BA1302	—	RECRUITING	2025-12-31	NCT06596915
Chongqing Precision Biotech Co., Ltd	CEA-targeted CAR-T cells	—	RECRUITING	2025-12-31	NCT06126406
Chongqing Precision Biotech Co., Ltd	CEA CAR-T cells	—	RECRUITING	2025-12-31	NCT06010862
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	TQB2102 for injection	—	RECRUITING	2025-12	NCT06115902
MBQ Pharma	MBQ-167	—	RECRUITING	2025-10-01	NCT06075810
Jiangsu HengRui Medicine Co., Ltd.	SHR-A1811	—	RECRUITING	2025-06	NCT06710990
Shandong Suncadia Medicine Co., Ltd.	HRS-1358	—	RECRUITING	2025-06	NCT05628870
Minerva Biotechnologies Corporation	huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells	—	RECRUITING	2025-01	NCT04020575
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	A166	—	ACTIVE NOT RECRUITING	2026-06-30	NCT05311397
Daiichi Sankyo	DS-1103a	—	ACTIVE NOT RECRUITING	2026-06-30	NCT05765851
AbbVie	ABBV-400	—	ACTIVE NOT RECRUITING	2026-07	NCT06084481
Enliven Therapeutics	ELVN-002	—	ACTIVE NOT RECRUITING	2026-07	NCT05650879
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2026-08-31	NCT03845166
Boundless Bio, Inc.	BBI-355	—	ACTIVE NOT RECRUITING	2026-09-30	NCT05827614
Eli Lilly	LOXO-783	—	ACTIVE NOT RECRUITING	2026-12	NCT05307705
MediLink Therapeutics (Suzhou) Co., Ltd.	YL202	—	ACTIVE NOT RECRUITING	2026-12	NCT05653752
Pfizer	Tucatinib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-12-31	NCT05382364
Roche	Inavolisib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2026-12-31	NCT03006172

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Breast Cancer

ER (Estrogen Receptor) (27) HER2 (22) EGFR (16) PD-1 (11) CDK4/6 (4) PIK3CA (2)

Novel Drugs by Company (New molecular entities)

Novartis 3 drugs

Roche 3 drugs

PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF

BLA 2020

KADCYLA

ADO-TRASTUZUMAB EMTANSINE

Pfizer 2 drugs

CELLTRION INC 2 drugs

SAMSUNG BIOEPIS CO LTD 2 drugs

Amgen 2 drugs

GE HEALTHCARE 1 drug

AstraZeneca 1 drug

Eli Lilly 1 drug

IMLUNESTRANT TOSYLATE

Viatris 1 drug

+12 more companies

Reformulations (19 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.